GSK2324 | CAS#1020567-30-9 | FXR agonist

MedKoo Cat#: 5351001 | Name: GSK2324

Description:

WARNING: This product is for research use only, not for human or veterinary use.

GSK2324 is a FXR agonist (EC50 = 50 nM, 102% efficacy).

Chemical Structure

GSK2324

CAS#1020567-30-9 (free)

Theoretical Analysis

MedKoo Cat#: 5351001

Name: GSK2324

CAS#: 1020567-30-9 (free)

Chemical Formula: C29H22Cl2N2O4

Exact Mass: 532.0957

Molecular Weight: 533.41

Elemental Analysis: C, 65.30; H, 4.16; Cl, 13.29; N, 5.25; O, 12.00

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

1020567-30-9 (free) 1020567-67-2 (potassium) 1020567-72-9 (sodium)

Synonym

GSK2324; GSK-2324; GSK 2324;

IUPAC/Chemical Name

6-(4-((3-(2,6-dichlorophenyl)-5-isopropylisoxazol-4-yl)methoxy)phenyl)quinoline-2-carboxylic acid

InChi Key

SZUHDKKQQZPOGX-UHFFFAOYSA-N

InChi Code

InChI=1S/C29H22Cl2N2O4/c1-16(2)28-21(27(33-37-28)26-22(30)4-3-5-23(26)31)15-36-20-10-6-17(7-11-20)18-8-12-24-19(14-18)9-13-25(32-24)29(34)35/h3-14,16H,15H2,1-2H3,(H,34,35)

SMILES Code

ClC1=CC=CC(Cl)=C1C2=NOC(C(C)C)=C2COC3=CC=C(C4=CC(C=CC(C(O)=O)=N5)=C5C=C4)C=C3

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 533.41 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Tarling EJ, Ahn H, de Aguiar Vallim TQ. The nuclear receptor FXR uncouples the actions of miR-33 from SREBP-2. Arterioscler Thromb Vasc Biol. 2015 Apr;35(4):787-95. doi: 10.1161/ATVBAHA.114.304179. Epub 2015 Jan 15. PubMed PMID: 25593129; PubMed Central PMCID: PMC4376635. 2: Vickers KC, Rader DJ. Nuclear receptors and microRNA-144 coordinately regulate cholesterol efflux. Circ Res. 2013 Jun 7;112(12):1529-31. doi: 10.1161/CIRCRESAHA.113.301422. PubMed PMID: 23743223; PubMed Central PMCID: PMC4043301. 3: de Aguiar Vallim TQ, Tarling EJ, Kim T, Civelek M, Baldán Á, Esau C, Edwards PA. MicroRNA-144 regulates hepatic ATP binding cassette transporter A1 and plasma high-density lipoprotein after activation of the nuclear receptor farnesoid X receptor. Circ Res. 2013 Jun 7;112(12):1602-12. doi: 10.1161/CIRCRESAHA.112.300648. Epub 2013 Mar 21. PubMed PMID: 23519696; PubMed Central PMCID: PMC3995747. 4: Bass JY, Caravella JA, Chen L, Creech KL, Deaton DN, Madauss KP, Marr HB, McFadyen RB, Miller AB, Mills WY, Navas F 3rd, Parks DJ, Smalley TL Jr, Spearing PK, Todd D, Williams SP, Wisely GB. Conformationally constrained farnesoid X receptor (FXR) agonists: heteroaryl replacements of the naphthalene. Bioorg Med Chem Lett. 2011 Feb 15;21(4):1206-13. doi: 10.1016/j.bmcl.2010.12.089. Epub 2010 Dec 23. PubMed PMID: 21256005.